- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- August 2024
- 150 Pages
Global
From €2538EUR$2,789USD£2,156GBP
- Report
- June 2021
- 50 Pages
China
From €2366EUR$2,600USD£2,010GBP
From €3186EUR$3,500USD£2,706GBP
- Report
- November 2023
- 276 Pages
Global
From €8647EUR$9,500USD£7,344GBP
- Report
- September 2021
- 152 Pages
Global
From €13648EUR$14,995USD£11,592GBP
Perjeta (pertuzumab) is a monoclonal antibody used in combination with other drugs to treat certain types of metastatic lung cancer. It is used in combination with chemotherapy and Herceptin (trastuzumab) to treat HER2-positive metastatic lung cancer. Perjeta works by blocking the HER2 protein, which is found in higher levels in some types of cancer cells. This helps to slow or stop the growth of cancer cells.
Perjeta is approved by the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic lung cancer in combination with chemotherapy and Herceptin. It is also approved for use in combination with Herceptin and chemotherapy as an adjuvant treatment for early-stage HER2-positive breast cancer.
Perjeta is manufactured by Roche, a Swiss multinational healthcare company. Other companies in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Merck. Show Less Read more
